Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Molecular imaging in oncology drug development.

Mudd SR, Comley RA, Bergstrom M, Holen KD, Luo Y, Carme S, Fox GB, Martarello L, Beaver JD.

Drug Discov Today. 2017 Jan;22(1):140-147. doi: 10.1016/j.drudis.2016.09.020. Epub 2016 Sep 28. Review.

PMID:
27693713
2.

An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.

Lucey BP, Gonzales C, Das U, Li J, Siemers ER, Slemmon JR, Bateman RJ, Huang Y, Fox GB, Claassen JA, Slats D, Verbeek MM, Tong G, Soares H, Savage MJ, Kennedy M, Forman M, Sjögren M, Margolin R, Chen X, Farlow MR, Dean RA, Waring JF.

Alzheimers Res Ther. 2015 Jul 29;7(1):53. doi: 10.1186/s13195-015-0136-z. eCollection 2015.

3.

Gabapentin-induced pharmacodynamic effects in the spinal nerve ligation model of neuropathic pain.

Hooker BA, Tobon G, Baker SJ, Zhu C, Hesterman J, Schmidt K, Rajagovindan R, Chandran P, Joshi SK, Bannon AW, Hoppin J, Beaver J, Fox GB, Day M, Upadhyay J.

Eur J Pain. 2014 Feb;18(2):223-37. doi: 10.1002/j.1532-2149.2013.00364.x. Epub 2013 Jul 16.

PMID:
23857727
4.

Monitoring tumor response to linifanib therapy with SPECT/CT using the integrin αvβ3-targeted radiotracer 99mTc-3P-RGD2.

Ji S, Zhou Y, Voorbach MJ, Shao G, Zhang Y, Fox GB, Albert DH, Luo Y, Liu S, Mudd SR.

J Pharmacol Exp Ther. 2013 Aug;346(2):251-8. doi: 10.1124/jpet.112.202622. Epub 2013 Jun 7.

5.

PET imaging for receptor occupancy: meditations on calculation and simplification.

Zhang Y, Fox GB.

J Biomed Res. 2012 Mar;26(2):69-76. doi: 10.1016/S1674-8301(12)60014-1.

6.

Pharmacological modulation of brain activity in a preclinical model of osteoarthritis.

Upadhyay J, Baker SJ, Rajagovindan R, Hart M, Chandran P, Hooker BA, Cassar S, Mikusa JP, Tovcimak A, Wald MJ, Joshi SK, Bannon A, Medema JK, Beaver J, Honore P, Kamath RV, Fox GB, Day M.

Neuroimage. 2013 Jan 1;64:341-55. doi: 10.1016/j.neuroimage.2012.08.084. Epub 2012 Sep 7.

PMID:
22982372
7.

Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist.

Esbenshade TA, Browman KE, Miller TR, Krueger KM, Komater-Roderwald V, Zhang M, Fox GB, Rueter L, Robb HM, Radek RJ, Drescher KU, Fey TA, Bitner RS, Marsh K, Polakowski JS, Zhao C, Cowart MD, Hancock AA, Sullivan JP, Brioni JD.

J Pharmacol Exp Ther. 2012 Oct;343(1):233-45. doi: 10.1124/jpet.112.194126. Epub 2012 Jul 19.

PMID:
22815533
8.

FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model.

Mudd SR, Voorbach MJ, Reuter DR, Tapang P, Hickson JA, Refici-Buhr M, Fox GB, Albert DH, Luo Y, Day M.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1669-72. doi: 10.1007/s00280-012-1840-z. Epub 2012 Feb 12.

PMID:
22327787
9.
10.

Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.

Mudd SR, Holich KD, Voorbach MJ, Cole TB, Reuter DR, Tapang P, Bukofzer G, Chakravartty A, Donawho CK, Palma JP, Fox GB, Day M, Luo Y.

Mol Imaging Biol. 2012 Oct;14(5):617-24. doi: 10.1007/s11307-011-0529-8.

PMID:
22167582
11.

Default-mode-like network activation in awake rodents.

Upadhyay J, Baker SJ, Chandran P, Miller L, Lee Y, Marek GJ, Sakoglu U, Chin CL, Luo F, Fox GB, Day M.

PLoS One. 2011;6(11):e27839. doi: 10.1371/journal.pone.0027839. Epub 2011 Nov 18.

12.

A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model.

Luo Y, Jiang F, Cole TB, Hradil VP, Reuter D, Chakravartty A, Albert DH, Davidsen SK, Cox BF, McKeegan EM, Fox GB.

Cancer Chemother Pharmacol. 2012 Apr;69(4):911-21. doi: 10.1007/s00280-011-1740-7. Epub 2011 Nov 12.

PMID:
22080168
13.

Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats.

Zhu CZ, Chin CL, Rustay NR, Zhong C, Mikusa J, Chandran P, Salyers A, Gomez E, Simler G, Lewis LG, Gauvin D, Baker S, Pai M, Tovcimak A, Brown J, Komater V, Fox GB, Decker MW, Jacobson PB, Gopalakrishnan M, Lee CH, Honore P.

Biochem Pharmacol. 2011 Oct 15;82(8):967-76. doi: 10.1016/j.bcp.2011.05.007. Epub 2011 May 17.

PMID:
21620806
14.

Latrepirdine increases cerebral glucose utilization in aged mice as measured by [18F]-fluorodeoxyglucose positron emission tomography.

Day M, Chandran P, Luo F, Rustay NR, Markosyan S, LeBlond D, Fox GB.

Neuroscience. 2011 Aug 25;189:299-304. doi: 10.1016/j.neuroscience.2011.05.032. Epub 2011 May 19.

PMID:
21619913
15.

ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models.

Jiang F, Albert DH, Luo Y, Tapang P, Zhang K, Davidsen SK, Fox GB, Lesniewski R, McKeegan EM.

J Pharmacol Exp Ther. 2011 Jul;338(1):134-42. doi: 10.1124/jpet.110.178061. Epub 2011 Apr 19.

PMID:
21505059
16.

Translational medicine special issue.

Day M, Fox GB, Marek GJ.

Biochem Pharmacol. 2011 Jun 15;81(12):1353-5. doi: 10.1016/j.bcp.2011.01.018. Epub 2011 Feb 4. No abstract available.

PMID:
21296055
17.

Paradigm shift in translational neuroimaging of CNS disorders.

Sakoğlu U, Upadhyay J, Chin CL, Chandran P, Baker SJ, Cole TB, Fox GB, Day M, Luo F.

Biochem Pharmacol. 2011 Jun 15;81(12):1374-87. doi: 10.1016/j.bcp.2010.12.029. Epub 2011 Jan 8. Review.

PMID:
21219879
18.

The Behavioral Assessment of Sensorimotor Processes in the Mouse: Acoustic Startle, Sensory Gating, Locomotor Activity, Rotarod, and Beam Walking.

Curzon P, Zhang M, Radek RJ, Fox GB.

In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2009. Chapter 8.

19.

Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals.

Chin CL, Upadhyay J, Marek GJ, Baker SJ, Zhang M, Mezler M, Fox GB, Day M.

J Pharmacol Exp Ther. 2011 Mar;336(3):709-15. doi: 10.1124/jpet.110.173880. Epub 2010 Dec 20. Erratum in: J Pharmacol Exp Ther. 2011 May;337(2):567.

PMID:
21172908
20.

Pharmacokinetic modeling and [¹²³]5-IA-85380 single photon emission computed tomography imaging in baboons: optimization of dosing regimen for ABT-089.

Chin CL, Carr RA, Llano DA, Barret O, Xu H, Batis J, Koren AO, Seibyl JP, Marsh KC, Tamagnan G, Decker MW, Day M, Fox GB.

J Pharmacol Exp Ther. 2011 Mar;336(3):716-23. doi: 10.1124/jpet.110.173609. Epub 2010 Dec 20.

PMID:
21172907
21.

Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease.

Luo F, Rustay NR, Ebert U, Hradil VP, Cole TB, Llano DA, Mudd SR, Zhang Y, Fox GB, Day M.

Neurobiol Aging. 2012 May;33(5):933-44. doi: 10.1016/j.neurobiolaging.2010.08.005. Epub 2010 Oct 18.

PMID:
20961663
22.

Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice.

Luo F, Rustay NR, Seifert T, Roesner B, Hradil V, Hillen H, Ebert U, Severin JM, Cox BF, Llano DA, Day M, Fox GB.

J Pharmacol Exp Ther. 2010 Dec;335(3):580-8. doi: 10.1124/jpet.110.172932. Epub 2010 Sep 7.

PMID:
20823195
23.

Structural abnormalities revealed by magnetic resonance imaging in rats prenatally exposed to methylazoxymethanol acetate parallel cerebral pathology in schizophrenia.

Chin CL, Curzon P, Schwartz AJ, O'Connor EM, Rueter LE, Fox GB, Day M, Basso AM.

Synapse. 2011 May;65(5):393-403. doi: 10.1002/syn.20857. Epub 2010 Oct 20.

PMID:
20803618
24.

D3 receptor target engagement in humans with ABT-925 using [11C](+)-PHNO PET.

Day M, Bain E, Marek G, Saltarelli M, Fox GB.

Int J Neuropsychopharmacol. 2010 Apr;13(3):291-2. doi: 10.1017/S1461145710000180. Epub 2010 Mar 3. No abstract available.

PMID:
20196920
25.

ABT-594 improves performance in the 5-choice serial reaction time task under conditions of increased difficulty, sub-chronic dosing, and in poorly-performing subjects.

Mohler EG, Franklin SR, Rueter LE, Fox GB, Decker MW, Browman KE.

Pharmacol Biochem Behav. 2010 Apr;95(2):146-57. doi: 10.1016/j.pbb.2009.12.019. Epub 2010 Jan 11.

PMID:
20064548
26.

Translational neuroimaging of the CNS: novel pathways to drug development.

Fox GB, Chin CL, Luo F, Day M, Cox BF.

Mol Interv. 2009 Dec;9(6):302-13. doi: 10.1124/mi.9.6.6. Review.

PMID:
20048136
27.

ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature.

Luo Y, Hradil VP, Frost DJ, Rosenberg SH, Gordon GB, Morgan SJ, Gagne GD, Cox BF, Tahir SK, Fox GB.

Anticancer Drugs. 2009 Jul;20(6):483-92. doi: 10.1097/CAD.0b013e32832c0acf.

PMID:
19398903
28.

Distinct spatiotemporal pattern of CNS lesions revealed by USPIO-enhanced MRI in MOG-induced EAE rats implicates the involvement of spino-olivocerebellar pathways.

Chin CL, Pai M, Bousquet PF, Schwartz AJ, O'Connor EM, Nelson CM, Hradil VP, Cox BF, McRae BL, Fox GB.

J Neuroimmunol. 2009 Jun 25;211(1-2):49-55. doi: 10.1016/j.jneuroim.2009.03.012. Epub 2009 Apr 5.

PMID:
19346009
29.

Differential responses in CBF and CBV to cocaine as measured by fMRI: implications for pharmacological MRI signals derived oxygen metabolism assessment.

Luo F, Schmidt KF, Fox GB, Ferris CF.

J Psychiatr Res. 2009 Aug;43(12):1018-24. doi: 10.1016/j.jpsychires.2008.11.009. Epub 2009 Jan 8.

PMID:
19135215
30.

Cloning and characterization of the monkey histamine H3 receptor isoforms.

Strakhova MI, Fox GB, Carr TL, Witte DG, Vortherms TA, Manelli AM, Miller TR, Yao BB, Brioni JD, Esbenshade TA.

Eur J Pharmacol. 2008 Dec 28;601(1-3):8-15. doi: 10.1016/j.ejphar.2008.10.026. Epub 2008 Oct 21.

PMID:
18977214
31.

Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.

Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, El Kouhen O, Hooker BA, Pai M, Wensink EJ, Salyers AK, Chandran P, Zhu CZ, Zhong C, Ryther K, Gallagher ME, Chin CL, Tovcimak AE, Hradil VP, Fox GB, Dart MJ, Honore P, Meyer MD.

J Pharmacol Exp Ther. 2009 Jan;328(1):141-51. doi: 10.1124/jpet.108.145011. Epub 2008 Oct 17.

PMID:
18931146
32.

Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic.

Day M, Balci F, Wan HI, Fox GB, Rutkowski JL, Feuerstein G.

Curr Opin Investig Drugs. 2008 Jul;9(7):696-706. Review.

PMID:
18600575
33.

Non-invasive characterization of beta-amyloid(1-40) vasoactivity by functional magnetic resonance imaging in mice.

Luo F, Seifert TR, Edalji R, Loebbert RW, Hradil VP, Harlan J, Schmidt M, Nimmrich V, Cox BF, Fox GB.

Neuroscience. 2008 Jul 31;155(1):263-9. doi: 10.1016/j.neuroscience.2008.04.021. Epub 2008 Jun 4.

PMID:
18534764
34.

Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties.

Tietje KR, Anderson DJ, Bitner RS, Blomme EA, Brackemeyer PJ, Briggs CA, Browman KE, Bury D, Curzon P, Drescher KU, Frost JM, Fryer RM, Fox GB, Gronlien JH, Håkerud M, Gubbins EJ, Halm S, Harris R, Helfrich RJ, Kohlhaas KL, Law D, Malysz J, Marsh KC, Martin RL, Meyer MD, Molesky AL, Nikkel AL, Otte S, Pan L, Puttfarcken PS, Radek RJ, Robb HM, Spies E, Thorin-Hagene K, Waring JF, Ween H, Xu H, Gopalakrishnan M, Bunnelle WH.

CNS Neurosci Ther. 2008 Spring;14(1):65-82. doi: 10.1111/j.1527-3458.2008.00037.x. Review.

35.

Minimization of potential hERG liability in histamine H3 receptor antagonists.

Black LA, Liu H, Diaz GJ, Fox GB, Browman KE, Wetter J, Marsh KC, Miller TR, Esbenshade TA, Brioni J, Cowart MD.

Inflamm Res. 2008;57 Suppl 1:S45-6. doi: 10.1007/s00011-007-0622-2. No abstract available.

PMID:
18345496
36.

Pharmacological MRI in awake rats predicts selective binding of alpha4beta2 nicotinic receptors.

Chin CL, Pauly JR, Surber BW, Skoubis PD, McGaraughty S, Hradil VP, Luo Y, Cox BF, Fox GB.

Synapse. 2008 Mar;62(3):159-68.

PMID:
18081183
37.

Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI.

Chin CL, Tovcimak AE, Hradil VP, Seifert TR, Hollingsworth PR, Chandran P, Zhu CZ, Gauvin D, Pai M, Wetter J, Hsieh GC, Honore P, Frost JM, Dart MJ, Meyer MD, Yao BB, Cox BF, Fox GB.

Br J Pharmacol. 2008 Jan;153(2):367-79. Epub 2007 Oct 29.

38.

Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.

Altenbach RJ, Liu H, Banfor PN, Browman KE, Fox GB, Fryer RM, Komater VA, Krueger KM, Marsh K, Miller TR, Pan JB, Pan L, Sun M, Thiffault C, Wetter J, Zhao C, Zhou D, Esbenshade TA, Hancock AA, Cowart MD.

J Med Chem. 2007 Nov 1;50(22):5439-48. Epub 2007 Oct 6.

PMID:
17918921
39.

A new family of histamine H3 receptor antagonists based on a natural product: discovery, SAR, and properties of the series.

Cowart M, Sun M, Zhao C, Witte DG, Miller TR, Krueger KM, Browman K, Fox GB, Bennani YL, Esbenshade TA, Hancock AA.

Inflamm Res. 2007 Apr;56 Suppl 1:S47-8. No abstract available.

PMID:
17806176
40.

Confounding effects of volatile anesthesia on CBV assessment in rodent forebrain following ethanol challenge.

Luo F, Li Z, Treistman SN, Kim YR, King JA, Fox GB, Ferris CF.

J Magn Reson Imaging. 2007 Sep;26(3):557-63.

PMID:
17729349
41.

Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity.

Cowart M, Gfesser GA, Browman KE, Faghih R, Miller TR, Milicic I, Baranowski JL, Krueger KM, Witte DG, Molesky AL, Komater VA, Buckley MJ, Diaz GJ, Gagne GD, Zhou D, Deng X, Pan L, Roberts EM, Diehl MS, Wetter JM, Marsh KC, Fox GB, Brioni JD, Esbenshade TA, Hancock AA.

Biochem Pharmacol. 2007 Apr 15;73(8):1243-55. Epub 2007 Feb 23.

PMID:
17371699
42.

Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test.

Day M, Pan JB, Buckley MJ, Cronin E, Hollingsworth PR, Hirst WD, Navarra R, Sullivan JP, Decker MW, Fox GB.

Biochem Pharmacol. 2007 Apr 15;73(8):1123-34. Epub 2006 Dec 9.

PMID:
17214974
43.

The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment.

Ballard ME, Basso AM, Gallagher KB, Browman KE, Fox GB, Drescher KU, Gross G, Decker MW, Rueter LE, Zhang M.

Psychopharmacology (Berl). 2007 Jan;190(1):1-11. Epub 2006 Nov 9.

PMID:
17093979
44.

Antisense knockdown of the rat alpha7 nicotinic acetylcholine receptor produces spatial memory impairment.

Curzon P, Anderson DJ, Nikkel AL, Fox GB, Gopalakrishnan M, Decker MW, Bitner RS.

Neurosci Lett. 2006 Dec 13;410(1):15-9. Epub 2006 Oct 20.

PMID:
17055644
45.

Pharmacological MRI in awake rats reveals neural activity in area postrema and nucleus tractus solitarius: relevance as a potential biomarker for detecting drug-induced emesis.

Chin CL, Fox GB, Hradil VP, Osinski MA, McGaraughty SP, Skoubis PD, Cox BF, Luo Y.

Neuroimage. 2006 Dec;33(4):1152-60. Epub 2006 Oct 4.

PMID:
17023182
46.

Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist.

El-Kouhen O, Lehto SG, Pan JB, Chang R, Baker SJ, Zhong C, Hollingsworth PR, Mikusa JP, Cronin EA, Chu KL, McGaraughty SP, Uchic ME, Miller LN, Rodell NM, Patel M, Bhatia P, Mezler M, Kolasa T, Zheng GZ, Fox GB, Stewart AO, Decker MW, Moreland RB, Brioni JD, Honore P.

Br J Pharmacol. 2006 Nov;149(6):761-74. Epub 2006 Oct 3.

47.

Pharmacological and functional magnetic resonance imaging techniques in CNS drug discovery.

Fox GB, McGaraughty S, Luo Y.

Expert Opin Drug Discov. 2006 Aug;1(3):211-24. doi: 10.1517/17460441.1.3.211.

PMID:
23495843
48.

Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety.

Basso AM, Bratcher NA, Gallagher KB, Cowart MD, Zhao C, Sun M, Esbenshade TA, Brune ME, Fox GB, Schmidt M, Collins CA, Souers AJ, Iyengar R, Vasudevan A, Kym PR, Hancock AA, Rueter LE.

Eur J Pharmacol. 2006 Jul 1;540(1-3):115-20. Epub 2006 May 6.

PMID:
16765941
49.

Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121.

Pan JB, Yao BB, Miller TR, Kroeger PE, Bennani YL, Komater VA, Esbenshade TA, Hancock AA, Decker MW, Fox GB.

Life Sci. 2006 Aug 29;79(14):1366-79. Epub 2006 Apr 26.

PMID:
16730751
50.

Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.

Esbenshade TA, Fox GB, Cowart MD.

Mol Interv. 2006 Apr;6(2):77-88, 59. Review.

PMID:
16565470

Supplemental Content

Support Center